Intellia EVP logs option grants, tax share sale

Intellia Therapeutics EVP and General Counsel James Basta reported routine equity compensation changes and a small tax-related share sale.

Rhea-AI Filing Summary

Intellia Therapeutics EVP and General Counsel James Basta reported routine equity compensation changes and a small tax-related share sale. On March 1, 2026, he received a grant of 65,829 stock options and 46,080 shares of common stock as equity awards. The option grant vests 33% on January 1, 2027, with the remaining 67% vesting in 24 equal monthly installments after that date. On March 2, 2026, 1,211 shares of common stock were sold at $13.78 per share in a mandatory sell-to-cover transaction to satisfy tax withholding on vested restricted stock units, described as not a voluntary trade by the reporting person.

Insider Trade Summary

Net Seller: 1,211 shares

Net Sell 3 txns

Insider BASTA JAMES

Role EVP, General Counsel

Sold 1,211 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,211	$13.78	$17K
Grant/Award	Stock Option (right to buy)	65,829	$0.00	$0.00
Grant/Award	Common Stock	46,080	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 65,829 contracts (Direct); Common Stock — 156,794 shares (Direct)

Footnotes (3)

1. F1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit
2. F2. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person.
3. F3. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Intellia (NTLA) report for James Basta?

Intellia reported that EVP and General Counsel James Basta received 65,829 stock options and 46,080 common shares as equity awards, and had 1,211 shares sold at $13.78 to cover tax withholding on vested RSUs.

Was the Intellia (NTLA) insider share sale by James Basta a voluntary trade?

The 1,211-share sale at $13.78 was described as a mandatory sell-to-cover for tax withholding on RSU vesting, and the filing states it does not represent a volitional trade by EVP and General Counsel James Basta.

What equity awards did Intellia (NTLA) grant to James Basta on March 1, 2026?

On March 1, 2026, James Basta received a grant of 65,829 stock options and 46,080 common shares tied to restricted stock units, reflecting ongoing executive equity compensation at Intellia Therapeutics as disclosed in the insider filing.

How do James Basta’s new Intellia (NTLA) stock options vest?

The 65,829 stock options granted to James Basta vest 33% on January 1, 2027. The remaining 67% vest in 24 substantially equal monthly installments thereafter, creating a multi-year vesting schedule aligned with continued service.

How many Intellia (NTLA) shares were sold in the tax sell-to-cover transaction?

The filing shows that 1,211 shares of Intellia common stock were sold at $13.78 per share. According to the footnote, this sale was solely to satisfy tax withholding obligations upon RSU vesting, not a discretionary sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BASTA JAMES

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/01/2026		A		46,080	A	$0	158,005	D
Common Stock	03/02/2026		S(2)		1,211	D	$13.78	156,794	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.78	03/01/2026		A		65,829		(3)	02/29/2036	Common Stock	65,829	$0	65,829	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit

2. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person.

3. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

	James Basta	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.